Anti-inflammatory Therapies for Cardiovascular Disease in 2026

Inflammation plays a central role in the initiation, progression, and destabilisation of atherosclerotic plaques. Endothelial dysfunction, leukocyte recruitment, and the release of pro-inflammatory cytokines contribute to plaque growth and vulnerability. Traditional risk factor modification, including statin therapy, addresses some inflammatory components indirectly, but a significant residual inflammatory risk persists in many patients with established cardiovascular disease (CVD). This residual risk is often quantified by persistently elevated levels of high-sensitivity C-reactive protein (hs-CRP), a biomarker of systemic inflammation.¹

Targeting Inflammatory Pathways

The concept of directly targeting inflammatory pathways to reduce cardiovascular events gained substantial traction following the Canakinumab Anti-inflammatory Thrombosis Outcome Study (CANTOS). This trial investigated canakinumab, a monoclonal antibody that selectively neutralises interleukin-1β (IL-1β). The trial demonstrated that canakinumab, at a dose of 150 mg subcutaneously every three months, led to a statistically significant reduction in the primary composite endpoint of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. The hazard ratio (HR) for the primary endpoint was 0.85 (95% CI 0.79-0.92; P < .001), compared with placebo. This effect was observed in patients with a history of myocardial infarction and an hs-CRP level of ≥2 mg/L.² The reduction in cardiovascular events was independent of lipid-lowering effects, as canakinumab did not significantly alter lipid profiles. However, an increase in fatal infections was observed in the canakinumab group (incidence rate 0.31 vs 0.18 events per 100 patient-years), necessitating careful patient selection.²

Beyond IL-1β inhibition, other inflammatory targets are under investigation. Colchicine, an ancient anti-inflammatory agent, has shown promise in reducing cardiovascular events. The Colchicine Cardiovascular Outcomes Trial (COLCOT) and the Low-Dose Colchicine for Secondary Prevention of Cardiovascular Disease (LoDoCo2) trial both demonstrated a reduction in cardiovascular events in patients with recent myocardial infarction or chronic coronary disease, respectively. In COLCOT, colchicine 0.5 mg daily reduced the primary composite endpoint of cardiovascular death, resuscitated cardiac arrest, myocardial infarction, stroke, or urgent hospitalisation for angina leading to revascularisation, with an HR of 0.77 (95% CI 0.61-0.96; P = .02).³ LoDoCo2 similarly reported an HR of 0.69 (95% CI 0.57-0.83; P < .001) for the primary composite endpoint of cardiovascular death, nonfatal myocardial infarction, nonfatal ischaemic stroke, or ischaemic-driven coronary revascularisation.⁴ The mechanism of action for colchicine involves inhibition of microtubule polymerisation, leading to reduced neutrophil activation and inflammasome inhibition.^3,4 Gastrointestinal side effects are the most common adverse events with colchicine.^3,4

Methotrexate, a folate antagonist with anti-inflammatory properties, was investigated in the Cardiovascular Inflammation Reduction Trial (CIRT). This trial enrolled patients with a history of myocardial infarction or multivessel coronary artery disease and type 2 diabetes or metabolic syndrome. CIRT did not demonstrate a reduction in cardiovascular events with low-dose methotrexate (15-20 mg weekly) compared to placebo. The HR for the primary composite endpoint of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death was 1.01 (95% CI 0.89-1.16; P = .84).⁵ This outcome suggests that a broad anti-inflammatory approach without specific targeting of the IL-1β pathway may not be effective in this population, or that the anti-inflammatory effects of methotrexate at these doses are insufficient to impact cardiovascular outcomes.⁵

Ongoing research continues to explore novel targets, including inhibitors of the NLRP3 inflammasome, which is a key component of the innate immune system involved in IL-1β activation. Other areas of interest include therapies modulating T-cell responses and B-cell activity, though these are largely in earlier phases of development for cardiovascular indications. The challenge remains to identify specific inflammatory pathways that are both amenable to therapeutic intervention and critical for driving cardiovascular events, while also ensuring a favourable safety profile.

Looking ahead to 2026, the landscape of anti-inflammatory therapies for CVD is expected to evolve with a greater emphasis on precision medicine. Biomarkers beyond hs-CRP, such as specific cytokines or genetic markers, may help identify patients most likely to benefit from targeted anti-inflammatory interventions and those at higher risk of adverse events. Further refinement of dosing strategies and combination therapies could also optimise efficacy while mitigating side effects.

The integration of these therapies into routine clinical practice will require robust risk-benefit assessments and clear guidelines for patient selection. While the promise of directly addressing inflammation in CVD is significant, ongoing research must continue to balance therapeutic efficacy with safety, particularly concerning immunosuppression and infection risk. The coming years will likely see a more nuanced approach to anti-inflammatory strategies, moving beyond broad-spectrum agents to highly targeted interventions based on individual patient inflammatory profiles.